By using cannabinoids and terpenes from hemp, HEMPCORP plans to provide organic medicine to global consumers in an effort to carve out a green future. Based in Uttarakhand, India, where hemp is legal, the company is set to fulfill the global demand for medicinal CBD, CBG, and other non-psychoactive cannabinoids.
Market projections predict that by 2024, the market size could grow by over 900% of the current one with the US market hitting over $20 billion. HEMPCORP plans to be a comprehensive global CBD products supplier in partnership with FMCG distributors.
One of the 100+ cannabinoids in the cannabis plant, CBD has proven to be beneficial in the treatment of various ailments, including cancer-related symptoms, with relatively no side effects in comparison to synthetic drugs.
HEMPCORP plans to utilize greenhouses and modular growth capsules to facilitate the production of a wide range of plant species with definitive efficiency assured by the use of artificial intelligence in tissue cultures.
HEMPCORP specializes in medical cannabinoid cultivation, processing, and refinement, with production expected to be in full swing in a year. The management team comprises of industry experts and entrepreneurs.